Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins

Return on Equity

Return on Assets

scPharmaceuticals Inc.

0.00%

-33.2%

-28.4%

OHR Pharmaceutical Inc.

0.00%

-71.5%

-66.8%

Liquidity

The Current Ratio and a Quick Ratio of scPharmaceuticals Inc. are 13 and 13. Competitively, OHR Pharmaceutical Inc. has 5.4 and 5.4 for Current and Quick Ratio. scPharmaceuticals Inc.’s better ability to pay short and long-term obligations than OHR Pharmaceutical Inc.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.